U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H17F3N2O4
Molecular Weight 406.3552
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLOCTAFENINE

SMILES

OCC(O)COC(=O)C1=C(NC2=CC=NC3=C(C=CC=C23)C(F)(F)F)C=CC=C1

InChI

InChIKey=APQPGQGAWABJLN-UHFFFAOYSA-N
InChI=1S/C20H17F3N2O4/c21-20(22,23)15-6-3-5-13-17(8-9-24-18(13)15)25-16-7-2-1-4-14(16)19(28)29-11-12(27)10-26/h1-9,12,26-27H,10-11H2,(H,24,25)

HIDE SMILES / InChI
Molecular Formula C20H17F3N2O4
Molecular Weight 406.3552
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including, https://www.aapharma.ca/downloads/en/PIL/2014/Floctafenine_PM.pdf

Floctafenine is an analgesic agent used for the treatment of pain. The drug exerts its anti-inflammatory action by inhibiting COX-1 and COX-2, with a slight preference towards COX-1. Floctafenine is marketed in Canada under the name Floctafenine and it is withdrawn in Europe (Idarac Brand name).

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Prostaglandin G/H synthase 1
30
Target ID: P23219|||Q5T7T7
Gene ID: 5742.0
Gene Symbol: PTGS1
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 2.33 mM [IC50]
Prostaglandin G/H synthase 2
51
Target ID: P35354
Gene ID: 5743.0
Gene Symbol: PTGS2
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 3.47 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
FLOCTAFENINE

Approved Use

FLOCTAFENINE (floctafenine) is indicated for short-term use in acute pain of mild and moderate severity.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.57 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33200/
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLOCTAFENIC ACID blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1200 mg single, oral
Recommended|Highest studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6120671
unhealthy
Health Status: unhealthy
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6120671
Disc. AE: Coma...
AEs leading to
discontinuation/dose reduction:
Coma (grade 4, 1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6120671
AEs

AEs

AESignificanceDosePopulation
Coma grade 4, 1 pt
Disc. AE
1200 mg single, oral
Recommended|Highest studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6120671
unhealthy
Health Status: unhealthy
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6120671
PubMed

PubMed

TitleDatePubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010-12
Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria/angioedema: update.
2007-03-15
Differential pulse cathodic voltammetric determination of floctafenine and metopimazine.
2007-03-12
Synthesis of some floctafenine derivatives of expected anti-inflammatory/analgesic activity.
2005-08
Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs.
2005-06
Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999.
2004-02
Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999.
2003-11
Determination of thiocolchicoside in its binary mixtures (thiocolchicoside-glafenine and thiocolchicoside-floctafenine) by TLC-densitometry.
2003-06
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria.
2000-08
[Identification of a metabolite of floctafenine in urinary calculi].
1987
Intracranial hypertension with etretinate.
1983-10-22
[Ionized fluorine in the plasma and urine of subjects treated with organofluorine drugs prescribed in rheumatology].
1979-02

Sample Use Guides

In Vivo Use Guide
The usual adult dose of floctafenine is 200 to 400 mg every 6 to 8 hours as required. The maximum recommended daily dose is 1200 mg.
Route of Administration: Oral
In Vitro Use Guide
The effects of floctafenine and its active metabolite on platelet COX-1, monocyte and 5-LO activities of whole blood in vitro were assessed by incubating increasing concentrations of floctafenine or floctafenic acid (0.001-100 mM) with peripheral whole blood samples drawn from healthy volunteers.
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:16:49 GMT 2025
Edited
by admin
on Wed Apr 02 09:16:49 GMT 2025
Record UNII
O04HVX6A9Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLOCTAFENINE
INN   JAN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
IDARAC
Preferred Name English
RU 15750
Code English
FLOCTAFENINE [JAN]
Common Name English
IDALON
Common Name English
FLOCTAFENIN
Common Name English
Floctafenine [WHO-DD]
Common Name English
RU-15750
Code English
R 4318
Code English
FLOCTAFENINE [MI]
Common Name English
NOVODOLAN
Common Name English
FLOCTAFENINE [MART.]
Common Name English
FLOCTAFENINE [USAN]
Common Name English
floctafenine [INN]
Common Name English
DIRALGAN
Common Name English
R-4318
Code English
BENZOIC ACID, 2-((8-(TRIFLUOROMETHYL)-4-QUINOLINYL)AMINO)-, 2,3-DIHYDROXYPROPYL ESTER
Common Name English
R-4138
Code English
2,3-Dihydroxypropyl N-[8-(trifluoromethyl)-4-quinolyl]anthranilate
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C257
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
WHO-VATC QN02BG04
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
WHO-ATC N02BG04
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C80553
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
DRUG BANK
DB08976
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
MERCK INDEX
m5405
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY Merck Index
PUBCHEM
3360
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
SMS_ID
100000080996
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
WIKIPEDIA
Floctafenine
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
CAS
23779-99-9
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
EVMPD
SUB07645MIG
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
DRUG CENTRAL
1178
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
INN
2936
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
EPA CompTox
DTXSID8057695
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
FDA UNII
O04HVX6A9Q
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
ChEMBL
CHEMBL2105075
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
MESH
C084600
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
ECHA (EC/EINECS)
245-881-4
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY
RXCUI
4444
Created by admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
PRIMARY RxNorm
Related Record Type Details
Structure of FLOCTAFENINE, (R)-
ENANTIOMER -> RACEMATE
Structure of FLOCTAFENINE, (S)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of FLOCTAFENIC ACID
METABOLITE -> PARENT
Percent of dose excreted in urine as metabolite.
WEIGHT PERCENT
URINE
Structure of FLOCTAFENIC ACID
METABOLITE -> PARENT
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
Related Record Type Details
Structure of FLOCTAFENINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966